Objectives Drug precipitation in vivo poses a significant challenge for the pharmaceutical industry. During the drug development process, the impact of drug supersaturation or precipitation on the in vivo behaviour of drug products is evaluated with in vitro techniques. This review focuses on the small and full scale in vitro methods to assess drug precipitation in the fasted small intestine. Key findings Many methods have been developed in an attempt to evaluate drug precipitation in the fasted state, with varying degrees of complexity and scale. In early stages of drug development, when drug quantities are typically limited, small-scale tests facilitate an early evaluation of the potential precipitation risk in vivo and allow rapid screening of prototype formulations. At later stages of formulation development, full-scale methods are necessary to predict the behaviour of formulations at clinically relevant doses. Multicompartment models allow the evaluation of drug precipitation after transfer from stomach to the upper small intestine. Optimisation of available biopharmaceutics tools for evaluating precipitation in the fasted small intestine is crucial for accelerating the development of novel breakthrough medicines and reducing the development costs. Summary Despite the progress from compendial quality control dissolution methods, further work is required to validate the usefulness of proposed setups and to increase their biorelevance, particularly in simulating the absorption of drug along the intestinal lumen. Coupling results from in vitro testing with physiologically based pharmacokinetic modelling holds significant promise and requires further evaluation.
Introduction
Oral drug absorption is a complex process that can be affected by a range of parameters, related to the drug, the formulation and the underlying physiology of the gastrointestinal tract (GIT). Molecular size, degree of ionisation, dissolution, precipitation, gastrointestinal (GI) transit times, luminal viscosity, pH, bile salt and phospholipid concentrations, cellular permeation and intestinal drug transport and metabolism are some examples of the factors which can affect absorption of a drug and, therefore, its bioavailability.
Possible supersaturation or precipitation are important parameters to consider, as they can significantly affect the bioavailability of an active pharmaceutical ingredient (API). Assessment of potential supersaturation and precipitation is critical, especially in cases where the API is a weak base with low aqueous solubility or a bio-enabling formulation is implemented.
Under fasting conditions, weakly basic drugs usually have higher solubility values in the acidic environment of the stomach compared with the small intestine. Due to the variability in pH values along the human GIT, weakly basic drugs have a propensity to precipitate. In particular, for weakly basic compounds, supersaturation can occur after transfer from the stomach to the small intestine. However, supersaturated states are thermodynamically unstable and the degree of supersaturation is the driving force for precipitation. Precipitation and drug absorption are competing processes in the GIT and excipient effects can be of critical importance. From 1981 until the end of 2006, 38% of the APIs approved in the U.S.A. for oral administration were basic molecules [1] and as new drug entities in current pipelines tend to be somewhat larger molecules (>500 Daltons) and more lipophilic, there is a need to develop reliable in vitro methods to simulate the transfer of the drug through the GIT and accurately predict their precipitation characteristics/kinetics in vivo.
The ultimate goal of bio-enabling formulations is enhanced intestinal absorption. To achieve this, pharmaceutical scientists often develop formulations, which are aimed at achieving and maintaining supersaturation, that is the so-called spring and parachute approach. [2, 3] In this way, a greater amount of drug is in solution for a longer period of time in the upper small intestine and therefore, available for absorption. Common methods to improve dissolution and achieve supersaturation include solid phase dispersions, lipid-based formulations and formulating with cyclodextrins. [4] [5] [6] Despite the increasing interest in producing these formulations, there is still a lack of mechanistic understanding about how to achieve and maintain a supersaturated state intraluminally. Therefore, design of these formulations remains a challenge. [7] In every case, precipitation of drug particles can result in impaired absorption of the API and reduced bioavailability. Consequently, it can jeopardise both the therapeutic efficacy and safety of the drug. Precipitation can further contribute to the large intra-and inter-individual variability in drug exposure often detected during development of new drug products [8] and can impair the chances of proving efficacy in clinical trials. [9] Currently, apparent supersaturation or precipitation of drug in vivo is assessed directly in the human lumen or indirectly using plasma profiles (from humans or animals), ex vivo methods, or in vitro methods. Luminal studies in humans provide the best source of information regarding the supersaturation or precipitation of different compounds. [10] [11] [12] [13] [14] Despite the valuable information obtained from luminal and in vivo methods in humans, as well as from ex vivo studies, [15] they are expensive, time-consuming and can raise ethical issues. Animal pharmacokinetic studies are also a valuable source of information, [16] but differences in the GI conditions between humans and the animal model can be an important source of error when assessing supersaturation or precipitation. Animal studies may also raise ethical issues and are costly to conduct. Methodologies for assessing drug supersaturation or precipitation in vitro allow for understanding and predicting the behaviour of an API/formulation and can facilitate the development of more efficient and safe drug products for patients. Assessing the supersaturation and precipitation kinetics of a compound is important in early development stages, before first in human studies, as well as in the later stages of formulation development. In early stage of drug development, usually a small amount of the candidate-API is available and, therefore, small-scale techniques are necessary. On the other hand, robust full scale in vitro setups are needed at the stage of formulation development for the evaluation of precipitation and supersaturation after administration of clinically relevant doses, as well as understanding supersaturation and precipitation kinetics in the presence of various excipients.
The purpose of this review article is to present an up-todate overview of the in vitro tools which have been proposed to predict in vivo precipitation, to understand their rationale and to outline strengths and weaknesses. This will highlight areas for optimisations and guide the evolution of the methodology.
Small-scale methods to assess drug precipitation
Small-scale in vitro setups facilitate the use of small quantities of the API available in the early stages of drug development. They may also be useful for the evaluation of prototype formulations. [17] In addition, the use of smallscale experiments allows for reducing the quantity of biorelevant media required, which helps to reduce expenses.
Smaller versions of the USP II dissolution apparatus have been developed. [18, 19] The mini-paddle vessels use 250 ml, instead of at least 500 ml used in the full-sized apparatus. Some of these downscaled apparatus have been shown to produce dissolution results comparable to the standard USP II apparatus. [19] However, in pharmaceutical profiling and early formulation development, an even smaller scale can be beneficial.
Single media tests
In early stage of drug development, evaluation of potential drug precipitation can be inferred by comparing solubility in simulated gastric with intestinal media. Solubility information can be obtained rapidly using high-throughput 96 well-based solubility screening tests. [20, 21] For example, the solubility of ketoconazole, as measured by the PASS (partially automated solubility screening) test, in Level II fasted state simulated intestinal fluid (FaSSIF) [22] (0.017 mg/ml) is much lower than in Level 0 simulated gastric fluid (SGF) (418.3 mg/ml) [20] , indicating possible precipitation upon transition from gastric to intestinal environment. Subsequent in vivo studies have shown precipitation of ketoconazole in the upper small intestine up to 16% of the administered dose.
Many of the high-throughput solubility tests use a solvent casting procedure, which raises concerns on potential changes of drug crystallinity upon removal of the solvent in the excipient matrix. [21] Another potential problem is that traces of solvent could also lead to an overestimation of solubility when the medium is added. While not attempting to capture the full complexity of the in vivo supersaturation or precipitation process, these high-throughput solubility screening tests provide useful information about solubility 'gaps' and thus, potential precipitation at an early stage under given conditions using only microgram quantities of drug.
Chandran et al., [23] proposed a small-scale approach using a turbidimetric spectrophotometry method to quickly evaluate the precipitation potential of a drug. With this method, a stock solution of drug was prepared using polyethylene glycol (PEG) 400 as a vehicle and precipitation inhibitors were added. Drug stock solution (100 ll) was added to a 96-well plate and mixed with an equal volume of deionised water. This setup measured absorbance at 500 nm, which is well above the absorbance range of any of the molecules tested, but provides a measure of light scattering due to the precipitation of drug, leading essentially to a turbidimetric endpoint. The authors hypothesised that the initial precipitation of fine particles caused a strong scattering of light, before agglomeration of particles resulted. A resulting increase in effective particle size and settling allows for increased transmission through the well, thus leading to decreasing absorption. The qualitative results using this method correlated well with traditional UPLC methods when examining the efficacy of different precipitation inhibitors, as both methods found that the 5% (w/w) d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS) in PEG 400 formulation was the most effective at preventing camphor precipitation. [23] Benefits of using the UV spectrometer include the simple and rapid analysis of drug precipitation at multiple time points, without the requirement of extra sample preparation or sample wastage. This test could be a useful tool to rapidly assess drug precipitation and the impact of excipients in early formulation development.
Tests with medium shift (solvent shift)
Yamashita et al., [24] used a solvent shift experiment to evaluate drug precipitation. In this method drug is initially dissolved in DMSO to produce a highly concentrated stock solution. The highly concentrated stock solution is diluted in Level II FaSSIF in a 96-well plate and drug precipitation is monitored by HPLC/UV analysis. This method is useful for comparing the effectiveness of different precipitation inhibitors, which can be added to FaSSIF. Yamashita et al., used this test to assess the efficacy of precipitation inhibitors with itraconazole. Results were found to correlate well with the full scale paddle dissolution experiment, as both methods identified HPMC-AS (hydroxypropyl methylcellulose-acetate succinate) as the most effective precipitation inhibitor.
Petrusevska et al., [25] used DMSO to deliver dissolved drug in a high-throughput test. McIlvaine's buffer (pH 6.8) with excipient concentrations of 0.001%, 0.01% and 0.1% (w/v) were initially dispensed into each well. The concentrated stock solution of drug in DMSO was added and the plate was shaken for 5 s to ensure adequate mixing. The plate was incubated and samples were removed at various time points up to 360 min. Experimental factors such as the shaking frequency, incubation temperature and effect of various DMSO concentrations in the setup were investigated. A DMSO concentration of ≤1% (v/v) in the assay was found to be acceptable. The efficacy of 23 different excipients to prevent precipitation of two poorly soluble neutral drugs, carbamazepine and fenofibrate, was examined. Distinct results were found for the two compounds, highlighting the case-specific nature of precipitation inhibitor effects. The authors concluded that this high-throughput test provided a reasonable starting point to select appropriate excipients to help prevent precipitation of drugs.
Petrusevska et al., [26] carried out a follow-up study investigating the use of light scattering and turbidity to evaluate drug precipitation and the efficacy of precipitation inhibitors. Light scattering was measured using a nephelometer, whereas turbidity was measured using a UV plate reader at 500 nm. Stock solutions of dipyridamole and fenofibrate in DMSO were tested using similar conditions as outlined in the previous experiment. Results were compared to those obtained using standard quantification methods, such as UPLC, to evaluate drug precipitation. The authors expressed a preference for using the light scattering method over the turbidity as it produced less false positives (4 vs 5) and less false negatives (0 vs 2) when examining the efficacy of different precipitation inhibitors.
Christfort et al., [27] developed a video-microscopic tool to assess the precipitation of tadalafil and the efficacy of precipitation inhibitors. Using a 96-well microplate, 30 ll of a tadalafil DMSO stock solution was added to FaSSIF with varying concentrations (0.0-5.0% w/v) of HPMC, acting as a precipitation inhibitor. Micrographs were obtained using the oCelloScope system TM (Philips Biocell A/S, Allerød, Denmark). The development of precipitation was monitored by both single and multi-particle analysis. Single particle analysis determined the induction time for precipitation to occur as the time taken for the first well-defined particle to appear into focus. Using single particle analysis, the effect of varying HPMC concentrations on the induction time for crystal growth and the growth in area of a single crystal was observed over time. As single particle analysis only focuses on the growth of a single crystal, it may not be representative of the total population of crystals. In contrast, multi-particle analysis enabled the analysis of the total population of particles by examining all areas of crystal growth within the field of view. Crystal growth was quantified by determining the percentage of the area of the microscopic field of view that is covered by particles and by counting the number of particles. Results of single and multi-particle analysis correlated with each other as both found that a 0.01% (w/v) concentration of HPMC was required to observe inhibition of precipitation, with maximum inhibition occurring at a concentration of 0.1% (w/v). This visual method of assessing precipitation has significant potential to increase the understanding of the precipitation kinetics in the intestine.
The lDiss system (Pion Inc., Billerica, MA, USA) employs UV fibre optics to obtain real-time experimental information about drug solubility and dissolution. Information about drug supersaturation and precipitation can also be inferred using the lDiss and can be used to study dissolution from drug powder or a miniaturised disc. [28, 29] Up to eight experiments can be run in parallel using volumes of media ranging from 1 to 10 ml. This method was employed to study dissolution for a wide variety of compounds, including poorly soluble drugs. [28] Palmelund et al., [30] developed an in vitro standardised supersaturation and precipitation method (SSPM) using the lDiss system. High concentration stock solutions of the model drugs were prepared using DMSO, and aliquots (200 ll) were added into 10 ml of Level II FaSSIF at 37°C. The model drugs tested were albendazole, aprepitant, danazol, felodipine, fenofibrate, and tadalafil. After each addition of stock solution, UV absorbance was measured using the in situ UV probes for 60 min or, if no precipitation was observed, for longer. Precipitation was detected by a shift in the baseline UV spectrum and decrease in drug concentration. Plum et al., [31] investigated the inter-lab reproducibility of the SSPM method, with testing carried out at seven different sites. Values obtained for three model drugs (aprepitant, felodipine, fenofibrate) for apparent drug supersaturation (aDS) and the induction time for detectable precipitation (t ind ) were compared across the various laboratories. While a direct comparison for aDS and t ind values between sites was not possible, it was found that 80% of the partners who submitted a full data set found the same rank-ordering of drugs (aprepitant > felodipine % fenofibrate) when comparing b-values, which was defined as the slope of the ln(t ind ) vs ln (aDS) À2 plot. [31] Tests with medium and pH shifts
Klein et al., [32] investigated the feasibility of creating a miniaturised transfer model system to model the transition from gastric to intestinal environment. Two different experimental setups were tested: a 96-well plate model and a mini-paddle apparatus model. In the 96-well model experiment, the drug is initially dissolved in Level 0 SGF (donor phase) before 30 ll of the donor phase is pipetted into the acceptor phase, consisting of 170 ll of either Level II FaS-SIF or Level II FeSSIF. Drug concentration was measured every 2 min with a UV microplate reader. In the mini-paddle setup, the drug is initially dissolved in 10 ml of Level 0 SGF and is added to 40 ml of either Level II FeSSIF or Level II FaSSIF, as shown in Figure 1 . Drug concentration Figure 1 Schematic of miniaturised transfer model system proposed by Klein et al. [32] Reproduced with permission from Springer.
was determined by HPLC. Hydroxybutenyl-b-cyclodextrin complexes of both tamoxifen and itraconazole were tested using both setups and the results were consistent between platforms; tamoxifen was not found to precipitate in either setup, whereas itraconazole precipitated by approximately 90% in both methods. The miniaturised intrinsic dissolution screening (MIND-ISS) setup uses minidiscs of compacted drug, typically 2-5 mg, to deliver drug into a 96-well plate. [33] The minidiscs are prepared in a custom-made holder, resulting in a drug surface area of 3 mm 2 . Dissolution medium (0.35 ml) is added into the wells and stirred. The minidiscs are added to the wells so that the drug is immersed in the dissolution media. After a set period of time, the minidiscs are transferred into a new well. This transfer into new media enables a pH shift, which may help to improve the biorelevance of the test by mimicking the changing environment along the GIT. [17] Drug concentrations are determined using UPLC, while Raman spectroscopy is used to analyse the solid state characteristics of the disc. The disc intrinsic dissolution rates (DIDR) calculated from the MINDISS setup, were closely correlated (R 2 = 0.9292) to larger scale drug disc dissolution tests.
Using the MINDISS setup, the DIDR of diclofenac sodium and diclofenac potassium in SGF, pH 1.2, was found to be identical to the free acid. [33] When testing both salt forms in Level 0 SGF, a layer of free diclofenac acid was formed on the surface of the disc which controlled the DIDR. This precipitation was thought to be due to the conversion of the salt forms of the drug to the less soluble free acid. A free base would be expected to demonstrate the converse behaviour that is to rapidly dissolve in acidic gastric conditions and precipitate in the more neutral intestinal environment.
Two-stage tests
The Sirius T3 instrument (Pion Inc.) is an automated titration system as shown in Figure 2 . [34] Gravestock et al., [35] used it to monitor precipitation of a wide range of acidic, basic and neutral drugs. It uses a fibre optic UV dip probe connected to a diode array UV spectrometer to obtain a real-time measurement of drug concentration. When examining dissolution and precipitation of drug, off-line sample analysis is susceptible to potential errors due to sample ageing. Real-time analytical technology, by contrast, avoids such errors. Drug dissolution and precipitation in 15 ml of buffered 0.15 M KCl was measured at four pHs: 1.9, 3.8, 5.2 and 7.2. The pH was initially 1.9 and increased every 30 min. The effect of pH on the dissolution and precipitation of drugs was observed; dissolution rates of acidic compounds increased with increasing pH, whereas neutral compounds had a relatively constant dissolution rate across the four pHs. Some basic drugs, such as dipyridamole, chlorpromazine HCl and clopidogrel bisulfate, precipitated as the pH was increased. Other basic drugs, such as haloperidol, maprotiline and propranolol, did not precipitate as the pH was increased. Jakubiak et al. [9] used dissolution data from the T3 to develop a dissolution and precipitation model. In their studies, the dissolution testing on the T3 was carried out using two different pH values (pH 2 and pH 6.5) to simulate gastric and intestinal conditions, respectively. Level II FaSSIF was used for simulating the conditions in the upper small intestine, while a simple phosphate buffer at pH 2 was used for simulating the conditions in the stomach. After 10 min at pH 2, concentrated FaSSIF was added to simulate the transfer from the gastric to the intestinal environment. The drug plasma profiles estimated using their model for dipyridamole and erlotinib showed a strong correlation to the human in vivo plasma profile, obtained from previous clinical studies.
Mathias et al., [36] developed a micro-dissolution test to examine the effect of changing media and pH on the Figure 2 Schematic of the Sirius T3 instrument. [34] Reproduced with permission from Springer.
dissolution, supersaturation and precipitation behaviour of drugs under conditions which aim to replicate the transit through the GI tract, as shown in Figure 3 . Drug, either as powder or suspension, was initially added to 7 ml of Level 0 SGF. After 20 min, 14 ml of a 1.5 times concentrated Level II FaSSIF solution was added to simulate the changes in conditions due to transfer from the stomach to the intestine. The pH of the resulting FaSSIF solution was 6.5 and the drug was incubated for a further 160 min. The weakly basic drugs ketoconazole and erlotinib were among the evaluated drugs using this test. Ketoconazole remained supersaturated for 55 min upon transition from gastric to intestinal conditions, before precipitating slowly over the next 75 min. Erlotinib precipitated rapidly to its equilibrium crystalline solubility upon addition of Level II FaSSIF.
Methods addressing intestinal absorption

Biphasic dissolution tests
A method to simulate the absorption step in dissolution tests is through the use of an organic layer on top of the aqueous donor layer. Drug partitioning from the aqueous to the organic layer helps to generate sink conditions in the donor layer, which can have a significant effect on drug precipitation. The disadvantage of biphasic experiments is that the organic layer is in direct contact with the aqueous layer; this can lead to effects which differ from in vivo drug absorption. For example, some of the organic layer may be solubilised and an emulsification could occur as a result. This issue can be especially pronounced if surface-active compounds are present in the biphasic experiments, which is rather common in bio-enabling formulations.
The miBldi-pH (miniscale biphasic dissolution model with pH-shift) is a small-scale biphasic dissolution test which incorporates a pH shift to evaluate drug release and precipitation, as shown in Figure 4 . [37, 38] The organic lipid layer acts as an absorptive sink as drug partitions from the aqueous phase into the organic phase. The system consists of 50 ml of aqueous media covered by a 15 ml octanol layer, which acts as an absorptive sink, in a miniaturised USP dissolution apparatus II. Drug concentration is determined by online UV-spectrometry. Frank et al., [37] investigated the utility of this system to predict the in vivo dissolution processes of two weakly basic drugs: dipyridamole and BIXX. Precipitation was observed for both drugs upon shift of the pH from an acidic gastric environment to the neutral intestinal environment. The correlation to in vivo data for both drugs was greatly improved using the biphasic dissolution model compared to single phase dissolution experiments. A level A IVIVC (in vitro-in vivo correlation) was established (R 2 = 0.95) between the fraction absorbed in vivo and the fraction dissolved in octanol for the BIXX formulations tested, whereas the single phase dissolution tests were not found to be predictive of in vivo performance.
The inForm (Pion Inc.) has also been proposed for biphasic dissolution experiments to study precipitation. The inForm setup employs a fibre optic UV dip probe to measure drug concentration in real time, and uses a potentiometric pH probe to monitor pH of the media in real time to facilitate in situ pH control. Biphasic experiments have been carried out using the inForm on a range of acidic, basic and neutral compounds using a solvent shift process. [39] Drugs were initially dissolved using DMSO to prepare a concentrated stock solution and samples were Figure 3 Schematic of the experiment carried out by Mathias et al. [36] Reprinted (adapted) with permission from Mathias et al. Copyright 2013
American Chemical Society.
added using an automatic liquid handling needle into the aqueous layer. The aqueous layer consisted of 40 ml of an acetate-phosphate buffer at pH 6.5, while the organic layer consisted of 30 ml of decanol. All the neutral and basic drugs were found to precipitate when injected into the aqueous layer at a dose level of 10 mg. Fenofibrate, a neutral compound, was added at two dose levels: 5 and 10 mg. Precipitation was observed at both dosing levels and the quantity of drug which partitioned into the lipid layer, was the same after 1 h. This indicated that in both cases fenofibrate rapidly precipitated to its equilibrium solubility in the aqueous layer and only dissolved fenofibrate was able to partition across from the aqueous into the lipid layer. To date, published data with respect to biphasic dissolution experiments using the inForm setup with a pH shift is very limited. [40] Compartmental methods using non-cellular biomimetic membranes
A two-chamber system has been proposed by Pion Inc. called the lFlux. [41] Drug concentrations in both the donor and acceptor chambers can be measured by fibre optic UV probes. A membrane separates the two chambers and a biomimetic membrane coated with lipids, which is a scaled-up version of the parallel artificial membrane permeability assay (PAMPA) membrane, is typically used. Uptake through the membrane into the acceptor chamber aims to represent drug absorption in vivo. Incorporation of an absorption step helps to improve the biorelevance compared with single chamber systems, as drug absorption can generate sink conditions in the donor chamber, which is beneficial when assessing drug precipitation. Zhu et al., [42] used the lFlux apparatus to study the effect of an increased gastric pH on the kinetic profiles of many drugs, including ketoconazole and nilotinib, as shown in Figure 5 . Initially 400 ll of drug suspension was added to 7 ml of SGF in the donor chamber. The pH of SGF was either at pH 2 or pH 6, simulating typical gastric pH and acid suppression, respectively. The acceptor chamber was filled with 21 ml of an acceptor sink buffer (ASB). After 20 min, 14 ml of 1.5 times concentrated Level II FaSSIF solution was added to the donor chamber and the concentrations in both chambers were monitored for 160 min. The resulting FaSSIF solution in the donor chamber had a pH of 6.5. In the experiment simulating normal gastric pH, ketoconazole maintained a supersaturated state for at least 20 min after addition of the concentrated FaSSIF and readily partitioned across the membrane into the acceptor compartment. In contrast, nilotinib was only transiently supersaturated after the addition of the FaSSIF solution in the experiment simulating normal gastric pH and appeared to precipitate quickly. The smaller surface area of the biomimetic membrane compared with the human intestine hampers the transfer of drug from the donor into the acceptor chamber. Therefore, precipitation may be overestimated in the donor chamber. This limitation must be considered when mimicking the relationship between absorption and precipitation using the lFlux. Figure 4 Schematic of the miBldi-pH apparatus. [38] Reproduced with permission from Elsevier.
Sironi et al., [43] investigated a dissolution/permeation system using an Ussing chamber with a Permeapad â acting as an intestinal barrier between the acceptor and donor side. Permeapad â consists of a thin layer of soy phosphatidylcholine on a hydrophilic support sheet. A good correlation has been achieved between the permeability coefficients found using Permeapad â with those using Caco-2 cells (R 2 = 0.75) [44] and the PAMPA membrane (R 2 = 0.76). The volume of media in donor and acceptor compartments was 7 and 6 ml, respectively. Phosphate-buffered saline (pH 7.35-7.45) was used as both acceptor and donor media. Hydrocortisone (BCS class II) suspension and hydrocortisone methanolate tablets were tested using this setup. For the suspension, a constant rate of permeation into the acceptor chamber was observed. This constant flux indicated that permeation through the membrane was the rate-limiting step. In contrast, the tablets had a variable rate of permeation through the membrane for the initial 3 h of the experiment. As the concentration plateaued in the donor chamber approaching equilibrium solubility after 3 h, a linear increase of drug was subsequently observed in the acceptor chamber. The area to volume ratio (0.25 cm 2 /ml) in this experiment was a limiting factor when trying to achieve a substantial decrease in donor chamber drug concentrations within a reasonable period of time. The authors calculated that it would take an area to volume ratio of 5.9 cm 2 /ml to achieve a 90% permeation of hydrocortisone into the acceptor chamber within 4 h. The inter-laboratory variability of these biomimetic membranes needs to be further investigated. The compatibility of the Permeapad â membrane with surfactants, co-solvents and biorelevant media, [45] and ability to be used over a long duration, up to 94.5 h in the experiment, are advantages compared with cellular membranes, such as Caco-2. To evaluate this setup's usefulness in assessing drug precipitation in the upper fasted small intestine, further studies must be carried out incorporating a pH shift from gastric to intestinal media.
Compartmental methods using cellular membranes
Ginski et al., [46] proposed a 'two-step' dissolution/Caco-2 system with the aim of simulating simultaneous dissolution and absorption in the GIT. This would enable prediction of the dissolution-absorption relationship for different compounds and allow a comparison with results from clinical studies. This continuous system consisted of a dissolution apparatus and a side-by-side diffusion cell. The drug is dissolved in the dissolution compartment and, after a filtration with a 10 lm filter, is transferred with a pump to a donor compartment, containing the Caco-2 monolayer. In this particular study, fast and slow dissolving formulations of piroxicam, metoprolol tartrate and ranitidine hydrochloride were tested. Generally, this two-step setup was able to reflect the qualitative dissolution-absorption relationships. This setup can be considered as a first attempt to couple dissolution with permeation through Caco-2 cell lines, although it is obvious that several more factors would need to be considered. For example, the lack of appropriate first-order gastric emptying, Gl transfer and the level of biorelevance of the media need to be taken into account to better simulate the in vivo drug absorption and accurately predict plasma concentrations.
Kobayashi et al., [47] proposed a system for predicting drug absorption using Caco-2 cells, which also accounted for the pH change from the stomach to the intestine. The drug was dissolved in a vessel that simulates the stomach (pH 1.0, volume of medium 3 ml) and a pump transferred the dissolved drug to a vessel (pH 6.0, volume of medium 3 ml) for pH adjustment. The solution with the adjusted pH was then transferred Figure 5 Schematic of dissolution-permeation experimental setup (lFlux apparatus) used by Zhu et al. [42] ASB, Acceptor Sink Buffer. Reproduced with permission from Springer.
to the compartment containing the Caco-2 monolayer. The same setup was also used by Sugawara et al., [48] where additionally the effect of pH change in the 'gastric vessel' (i.e. simulating achlorhydria or patients administered with proton pump Inhibitors or H2-receptor antagonists) was evaluated. Significant differences were found in the cumulative permeation of two albendazole formulations at raised and normal gastric pH in this experiment. These results qualitatively agreed with a previous rabbit study carried out using the same albendazole formulations. [49] However, the culturing time required for the Caco-2 cells limits the throughput capacity of this method. Issues concerning the poor reproducibility of results, and incompatibility with some solubilising excipients (e.g. surfactants) and some media (e.g. Level II FeSSIF) also further limit the use of Caco-2 cell monolayers as intestinal barriers in studies examining intestinal precipitation. [45] In the same logic of assessing simultaneously dissolution and permeation through cell monolayers, Kataoka et al., [50] introduced a dissolution/permeation system (D/ P), which consisted of an apical and basolateral compartment mounted with a Caco-2 monolayer. The volume of apical and basolateral compartments was 8 and 5.5 ml, respectively. Magnetic stirrers were placed in both compartments and Hanks balanced salt solution issued in both sides as a transport medium. Kataoka et al., [51] utilised the same technique but improved its biorelevance using a modified Hank's balanced salt solution containing sodium taurocholate (3 mM) and lecithin (0.75 mM) as a transfer medium. Overall, the D/P system was proposed to be a useful tool for formulation selection during drug development. [52] Nonetheless, it is mainly used for powders or suspensions and despite the use of a more biorelevant transfer medium, the D/P system is far from properly mimicking in vivo conditions, such as hydrodynamics, fluid volumes, GI transfer etc. Furthermore, to the best of our knowledge, it has not been used to study precipitation or supersaturation kinetics.
Full-scale methods to assess drug precipitation
In late stages of formulation development, where larger amounts of the API are available, full-scale methods and setups are required to accurately characterise and predict the behaviour of the formulation, after administration of clinically relevant doses. These full-scale techniques aim to evaluate the supersaturation or precipitation of the drug product and to help understand the effect of different excipients on its kinetics. The main goal is to link the bioavailability of the drug product to the amount of drug which is in solution in the upper small intestine, where absorption mainly takes place.
Compendial apparatus and methods
USP I and USP II dissolution apparatus and methods
The basket (USP I) and paddle (USP II) apparatus were first introduced into the United States Pharmacopeia in the 1970s for evaluating the dissolution characteristics of oral drug products. [53] They have primarily been used to fulfil a QC function for testing a variety of oral dosage forms [54] and provide a large volume of media for a dosage form to dissolve in a well-stirred environment. [55] Dissolution testing using either the USP I or USP II apparatus is conducted under various parameters and conditions, including variations in hydrodynamics, type and volume of dissolution medium. [56] Typically the volumes used in the basket/paddle apparatus range from 500 to 1000 ml and these large volumes are often useful to generate sink conditions required to achieve complete dissolution. However, they are far in excess of volumes in the human stomach and intestine, which do not typically exceed 250 ml in the fasted stomach and 30-100 ml in the fasted upper small intestine. [57, 58] The simple aqueous buffers typically used in the USP methods reflect the composition of the GI contents to a limited extent. This can lead to a misinterpretation of the in vivo dissolution profile, where supersaturation, precipitation and re-dissolution might occur. Apart from the pharmacopoeial buffers, different levels of biorelevant media can be used for simulating the composition of the GI fluids. Biorelevant media have demonstrated advantages over compendial media when assessing drug performance in vivo. [22, 59, 60] Wagner et al., [60] carried out an experiment comparing the use of compendial and biorelevant media with the USP II apparatus for Compound A, a basic BCS class IV drug. It was found to have a much greater solubility and dissolution rate constant (z value) in biorelevant media representing the upper fasting intestine, compared with simple media at the same pH. The STELLA â software was used to model the predicted drug plasma profiles from the dissolution data and a stronger correlation to the human in vivo data was observed from the profiles predicted from the dissolution experiments using biorelevant media. The transfer process from the stomach through different parts of the intestine is not taken into consideration when using the compendial USP I and USP II dissolution methods. This process is important for IR formulations of weak bases, as the drug might precipitate as it enters the small intestine, and for MR formulations, which are commonly designed to deliver the drug to distal, as well as proximal sites of the GIT.
The 'dumping test'
Kambayashi et al., [61] proposed a simple pH-shift test, the so-called dumping test, in which 50 ml solutions of two weak bases, dipyridamole and ketoconazole, in 0.02 N HCl at various concentrations were 'dumped' into 450 ml of FaSSIF-V2. In this case, Level II FaSSIF-V2 had higher concentration of sodium taurocholate and lecithin, so after 'dumping' of the drug solutions, the final concentrations of sodium taurocholate and lecithin in the dissolution vessel corresponded to the composition of Level II FaSSIF-V2. The results from this in vitro setup were successfully coupled with STELLA â software and a predictive model for the total and dissolved concentration in small intestine for both drugs, after oral administration in the fasted state was established. The advantage of this simple approach is that it could be used as an early assessment and pre-screening tool for drug precipitation during early stages in drug product development to facilitate the design and development of new drug products. The performance of this method as a screening tool and its possible preference over the more complicated transfer methods should be further investigated, especially when solid dosage forms are considered.
Compartment methods not addressing intestinal absorption
Closed systems
It was Kostewicz et al., [62] who first introduced the socalled transfer model, which simulates the transfer of drug from the stomach to the upper small intestine. This setup is a two compartment compendial dissolution method where contents of the vessel, in which dosage form's performance under simulated gastric conditions (donor compartment) is evaluated, are transferred with a pump into another vessel, where the conditions in the small intestine are simulated (acceptor compartment) ( Figure 6 ). In that study, the donor compartment containing the dissolved drug in 125 ml SGF was transferred at a constant rate between 0.5 and 9.0 ml/min (values within the observed physiological range) into the acceptor compartment 500 ml Level II FaSSIF. The results indicated that a combination of data collected with the transfer model, solubility data and dissolution data should lead to better prediction of the in vivo behaviour of poorly soluble weak bases. Furthermore, it was clear that gastric emptying rates may play an important role on the precipitation kinetics. Such effects of the transfer rate can be considered by mathematical modelling as it has been proposed for the in vitro transfer test by Arnold et al. [63] The classical transfer test was here used together with an on-line particle analyser and in-line Raman spectroscopy to study the kinetics of drug precipitation. A nucleation and growth model was used at two transfer rates (4 and 9 ml/min) and experimental results for dipyridamole were in good agreement with the model.
Due to the shortcomings of the initial transfer model, such as the zero order rate of drug pumping from the donor compartment to the acceptor compartment, Ruff et al., [64] attempted to optimise the experimental conditions of the originally proposed transfer model, using ketoconazole as model compound. In this study, the 'average' physiological GI conditions were taken into consideration, while the impact of extreme conditions was also evaluated. To reflect fasting gastric emptying behaviour in vivo, a first-order transfer rate with half-life of 9 min was used. Generally, the optimised transfer model by Ruff et al. was successful in simulating the in vivo dosage form performance. Nonetheless, one disadvantage of this model is that it fails to take the absorption process into consideration, which might be crucial to whether precipitation occurs or not, and thus also in determining drug plasma concentrations. It was concluded that this in vitro model over-predicted the precipitation behaviour of ketoconazole. The authors also mention that for BCS Class II compounds, which have high or moderate permeability values, in vivo precipitation may be reduced due to the continuous in vivo absorption of the drug through the intestinal mucosa. This may not apply to BCS Class IV drugs with low permeability characteristics, where possible precipitation seriously affects the amount of drug available for absorption. To circumnavigate the lack of absorption in the in vitro model, the authors coupled the results obtained with the transfer model to a PBPK model, where absorption was taken into account. With Figure 6 The 'transfer model' proposed by Ruff et al. [64] Reproduced with permission from Elsevier.
this approach not only was precipitation shown not to occur in the intestinal compartment, but the plasma profile was accurately simulated in humans.
Open systems
The artificial stomach duodenal (ASD) model has two chambers representing the stomach and the duodenum. In the standard setup, the gastric and duodenal chambers have a maximum capacity of 400 and 50 ml, respectively, [65] with fluid transfer controlled by a series of five pumps, accounting for stomach and duodenal secretions and chamber emptying. The initial starting volumes in the chambers, the flow rate of fresh media into the chambers and the emptying rate from the chambers can all be adjusted to fit the experimental requirements (e.g. in vitro modelling of fasted/fed state, human or dog model). [65] [66] [67] [68] Dilute HCl and Level II FaSSIF are typically used as gastric and duodenal fluid, respectively. Dissolution is the primary process which occurs in the ASD's gastric and duodenal chambers. However, concurrent precipitation can also occur in these chambers. The ASD model has been used to examine the relative bioavailability of various drugs. [65, 66, 69] When assessing the performance of the weakly basic drug galunisertib, the ASD showed that the formulations maintained supersaturation upon transition into the duodenal chamber and that no significant precipitation occurred throughout the experiment (150 min). [67] To account for the information obtained from the ASD model in the absorption modelling, a precipitation time of 11 h was estimated by the GastroPlus â software. This estimate exceeds the usual small intestine transit times which are observed in vivo and confirms that galunisertib could maintain supersaturation in the small intestine for a longer period than 15 min, which is the default value used in GastroPlus â when no experimental data are available. Combining the ASD data and other biopharmaceutical results (e.g. permeability) as inputs for GastroPlus â , the simulated plasma concentration profiles for the three tablet formulations were found to have AUCs of between 90% and 105% of the observed human clinical data. The model was able to successfully rank the in vivo bioavailability of the different formulations of galunisertib used in the clinical trials. The ASD model was also used to check the effect of gastric pH on LY2157299, a weakly basic BCS class II drug, which had showed variability of absorption in early studies carried out in dogs. [68] Compared with humans, dogs have a larger variability of basal gastric pHs, which can be a source of error when assessing the in vivo performance of drugs with a pH-dependent solubility in dogs. To model the variability in dog gastric pH, experiments were carried out in the ASD using gastric fluid at pH 2 and pH 4.5, using 10 À2 N HCl or 10 À4 N HCl, respectively. While the ASD model was able to qualitatively predict the effect of variability of stomach pH on the bioavailability of LY2157299, it overestimated the influence of the raised gastric pH on the absorption of LY2157299.
Takeuchi et al., [70] evaluated the performance of a threecompartment setup (Gastrointestinal Simulator-GIS) for predicting in vivo dissolution and precipitation. The three compartments of the GIS represent the stomach, the duodenum and the jejunum, where different buffer species, volumes and pH values were used to mimic the in vivo conditions. The fluid transfer rate from the gastric to the duodenal compartment was set at a first-order rate with a half-life between 5 and 10 min. In this particular setup, paddles were adjusted to give a high-speed burst at certain intervals to simulate the contractions in the stomach and the duodenum. Gastroplus â software was used to determine the in vitro gastric emptying time, which provided the best fit to in vivo data for two BCS Class I drugs, propranolol and metoprolol. Overall, the GIS was able to predict the in vivo performance of the investigated compounds. The GIS setup was also used by Matsui et al., [71] to investigate the impact of elevated gastric pH. When coupled with in silico modelling GIS could be useful for assessing in vivo precipitation of BCS Class II weakly basic compounds, but incorporation of an absorptive site, to mimic the continuous drug removal from the intestine, might be beneficial for enhancing its in vivo predictability.
A slightly modified form of the GIS (mGIS), was used by Tsume et al., [72] to investigate the absorption kinetics of the weakly basic drug dasatinib. In this study, the in vitro results from the dissolution experiments performed in the USP apparatus II and mGIS, were coupled with Gastroplus â to predict plasma concentrations. The predicted plasma profiles were compared with clinical data. The dissolution profiles of dasatinib acquired with the USP apparatus II did not indicate precipitation and resulted in absorption profiles, which did not match the human data.
On the other hand, the dissolution profiles acquired with the mGIS exhibited supersaturation and precipitation of dasatinib and, when coupled with Gastroplus â , resulted in better plasma concentration predictions. Despite the fact that the PBPK model underestimated the overall Cmax and AUC, something that could be partially attributed to underestimated permeability values, the study clearly demonstrated the benefit of assessing drug supersaturation or precipitation with a more complex setup. Tsume et al., [73] have used also the GIS to assess the supersaturation/precipitation kinetics of the two weakly basic compounds; dipyridamole and ketoconazole. For both compounds, and in accordance to previous studies, [10, 62, 64, 74] the precipitation rates observed in the intestinal compartments of GIS were overestimated, most likely due to lack of an absorptive compartment. This study highlighted once more the importance of accounting also for the absorption process when assessing precipitation with various setups in vitro.
Compartment methods which attempt to account of absorption
Although models which do not account for the intestinal absorption process can be useful in predicting in vivo drug supersaturation or precipitation, the in vivo performance of a drug product is highly dependent not only on the GI transfer, but also on other important parameters, such as the intestinal permeability. As mentioned previously, for drugs with high or moderate permeability values, in vitro setups can overpredict in vivo precipitation as the sink conditions created by continuous removal of the drug through the gut wall are not simulated in vitro. To account for drug absorption in the in vitro experiment, a number of models have been setup.
Using appropriate flow rates to take into account both absorption and transit process
These methods have been proposed primarily for evaluating products of highly permeable APIs. Psachoulias et al., [74] introduced a three-compartment setup for the prediction of intraluminal precipitation of ketoconazole and dipyridamole. This setup consisted of a gastric, a duodenal and a reservoir compartment. The reservoir compartment contained concentrated Level II biorelevant medium with the purpose of keeping pH values, lecithin and bile salt concentrations constant in the duodenal compartment, thereby compensating for the dilution that occurs when the simulating gastric fluid is pumped into the duodenal compartment. During each experiment, the volume of the medium in the duodenal compartment was kept constant at 60 ml. The flow rates between the compartments were regulated by a multi-channel peristaltic pump and a first order gastric emptying rate of 15 min was used. The contents of the duodenal compartment were completely renewed with fresh medium every 15 min. Using this experimental setup the measured in vitro duodenal compartment concentrations were in line with the luminal concentrations measured in healthy volunteers in previously performed clinical studies. [10, 75] Dose-dependent in vitro precipitation was observed for ketoconazole. However, XRPD studies indicated differences in the solid state characteristics of the precipitates; in vitro the precipitate of ketoconazole was crystalline, but in vivo it was amorphous. Despite the good results presented with this methodology, the equipment is not commercially available, thus restricting its application in the pharmaceutical industry.
Recently, Kourentas et al., [76] introduced a new setup (biorelevant gastrointestinal transfer system-BioGIT) for simulating Gl transfer and assessing duodenal concentrations, drug supersaturation or precipitation of highly Figure 7 The BioGIT system proposed by Kourentas et al.
[76] F 1 and F 2 are the incoming flow rates and F is the outgoing flow rate (F = F 1 + F 2 ).
Reproduced with permission from Elsevier.
permeable APIs, using commercially available equipment. This setup also consists of three compartments: gastric, duodenal and reservoir compartment ( Figure 7 ). The reservoir compartment is used for maintaining the composition of the medium in the duodenal compartment constant. Gastric emptying half-life is 15 min. The volume of the dissolution medium in the gastric compartment is 250 ml (10 ml resting volume, plus 240 ml to account for administration with a glass of water) and the volume of the duodenal compartment is set at 40 ml. Fluid from the duodenal compartment is moved away with a constant flow rate of 11.6 ml/min, so that the volume in the duodenal compartment is kept constant throughout the experiment. These flow rate and volumetric values were estimated from luminal data previously collected from healthy adults. In this study, the ability of the BioGIT model to predict intraluminal concentrations of dipyridamole, ketoconazole and posaconazole was evaluated. With the BioGIT setup the precipitated fraction in vivo was successfully predicted in every case. [77, 78] The method has been shown to be useful for providing information on the impact of GI transfer on intraluminal concentrations of drugs, which are given as fast disintegrating tablets and capsules, dispersions or solutions. Recently, BioGIT data were successfully used for informing PBPK modelling software and predicting the plasma profile of a moderately precipitating salt of weak base. [79] However, one should note here, that BioGIT has been designed to simulate intraluminal concentrations of highly permeable drugs, after administration in the fasted state. Therefore, flow rates might need to be adjusted to simulate concentrations of drugs with different permeability characteristics. [80] Evaluation of intra-and inter-laboratory reproducibility of BioGIT data is currently in process. [81] Utilising a similar approach, based on the compendial dissolution apparatus II, Gu et al., [82] described a multicompartmental model with four compartments, comprising of a gastric, intestinal, absorption and a reservoir compartment, to maintain the composition in the intestinal compartment (Figure 8 ). The novelty of this setup was the addition of the 'absorption compartment', to simulate the uptake of drug across the intestinal membrane. All compartments were placed in a water bath at 37°C temperature and the pH in each vessel was maintained at a constant Figure 8 Multicompartment dissolution system by Gu et al. [82] Vessel 1 'gastric' compartment simulating the stomach conditions; Vessel 2: 'intestinal' compartment simulating the intestinal conditions; Vessel 3: 'absorption' compartment simulating absorption; Vessel 4: reservoir vessel containing the dissolution medium identical to that in Vessel 2. Reproduced with permission from Elsevier. Figure 9 Schematic diagram of the simulated stomach duodenum model (SSD). [8] Reprinted (adapted) with permission from Mitra et al.
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value. The drug was transferred with different flow rates between the compartments, the volumes of which were kept constant and controlled by a peristaltic pump. Vessel 1 contained 250 ml of dissolution medium to simulate the available volume of gastric fluids in the stomach in the fasted state. Vessel 2 contained 250 ml of dissolution medium, simulating the composition of the upper small intestine, and after the inflow from vessel 1 for 1 h the volume in vessel 2 increased to 500 ml. Vessel 3 contained 600 ml of ethanol and 100 ml of 0.1 N HCl solution to maintain drug concentrations below their solubility values throughout the experiment. In this study, the precipitation kinetics of two weak bases, cinnarizine and dipyridamole was investigated. It was concluded that this method could successfully predict drug precipitation in the lumen, and the results from this multi-compartmental system correlated better with the in vivo data compared with the conventional dissolution methods. Cinnarizine and dipyridamole were found to have significantly different precipitation characteristics, despite both being fully dissolved at gastric pH. Approximately 40% of the cinnarizine was found to precipitate in the intestinal vessel compared to <10% of the dipyridamole dose. The setup from Gu et al., simulates the absorption process in a simple dissolution apparatus and no complex additions/methods are needed. Furthermore, the flow rates between the intestinal and absorption compartments can be adjusted to reflect different permeability values, thus facilitating its use in the investigation of precipitation kinetics for APIs with different permeability properties. One issue may be the use of filter during the transfer of contents from vessel 1 to vessel 2. Also, a challenge of this setup is that it is difficult to adjust the flow rates to the absorption compartment so that they would correlate with in vivo permeability values. Mitra et al., [8] proposed yet another setup to simulate the dynamic environment of the GIT; the 'simulated stomach duodenum' model (SSD) (Figure 9 ). The SSD model was modelled after the system described by Carino et al., [66] (Section Open systems) and it is a four-compartment model, where the removal of drug from the duodenum is also taken into account. The study explored the ability of the SSD to predict the supersaturation of different dose strengths of dipyridamole under fasted conditions, as well as to investigate the impact of different surfactants, which are commonly used in oral preparations. In the SSD model, basal volumes in both gastric and duodenal compartment were used, based on mean fluid volumes previously reported in clinical studies in fasted adults. The basal gastric volume was set at 50 ml and the duodenal at 30 ml. The gastric emptying was simulated by a first-order pattern with a half-life of 15 min, until the basal gastric volume was restored. Afterwards, the gastric emptying was kept constant at 1.7 ml/min. The setup was able to predict the supersaturation kinetics of dipyridamole when compared with in vivo data. Furthermore, the effect of different surfactants commonly used in oral preparations, as well as the effect of different gastric emptying patterns on dipyridamole supersaturation was investigated. The SSD model provided good correlation of the amount of drug in solution in the duodenal compartment of the SSD to the bioavailability of different dosage strengths of dipyridamole in vivo. However, again this setup does not take into account the application of different flow rates to adjust for low permeability values. Furthermore, the SSD model is not based on a commercially available setup, such as the USP II dissolution apparatus, and agitation is performed using magnetic stirrers at 200 rpm, which entails hydrodynamics that are less reproducible and not physiologically relevant. To investigate its usefulness in predicting drug precipitation, more studies with different compounds are needed.
Another multicompartment method incorporating a chamber simulating the systemic circulation was proposed by Selen et al. [83] The FloVitro TM (Dow Chemicals, Midland, MI, USA) is a three compartment system with chambers simulating the gastric, intestinal and systemic compartments (cells) and flow rates between cells. The fluid volume in the cells varies depending on the compound tested; typically 40 ml in the gastric cell, 200 ml in the intestinal cell and 1-2 l in the systemic cell are used. The primary use of the FloVitro TM has been to predict the in vivo plasma profile based on the profile which is achieved in the systemic cell using a variety of drugs, including ibuprofen, furosemide, paracetamol and doxycycline hydrochloride. [83, 84] The effect of fed or fasted state media has also been examined on the dissolution profiles of danazol and furosemide. [85] However, there have not been any publications to date illustrating its application to precipitation of poorly soluble weak bases and further studies will need to be undertaken.
Simulating the intestinal epithelial barrier
Motz et al., [86] introduced a system which consists of the flow through dissolution apparatus (USP apparatus IV) and a flow through permeation module. The latter includes an open apical and a closed basolateral compartment with a Caco-2 monolayer between them. The flow rates of the dissolution medium which was transferred from the USP IV to the permeation module had to be carefully adjusted, to assure the viability and integrity of the Caco-2 cell membrane. Indeed, the authors suggested the use of a stream splitter, which successfully allowed the combination of compendial and commercially available USP apparatus IV with a permeation/Caco-2 compartment. Krebs buffer was chosen as the dissolution and permeation buffer for the installation of this apparatus. While the use of biorelevant dissolution media could be more physiologically relevant and perhaps produce better results, the authors acknowledged that a first evaluation of this new setup was the initial scope of the study. Even though the Caco-2 cell monolayers is a useful in vitro technique to assess drug permeation and allows good predictions of in vivo drug permeability, [87] [88] [89] their implementation in methods for assessing precipitation in the donor compartment may not be straightforward, as also mentioned above in the presentation of small scale methods to assess precipitation. These limitations include different cultures of Caco-2 cells resulting in data variability, difficulty in predicting paracellular transport as a result of tighter junctions between the colonic cells and long period of time required for cell culture. [90] The lower surface area for the Caco-2 cell line compared with the intestinal membrane is also disadvantageous when examining the relationship between precipitation and absorption.
As mentioned previously, an alternative to the absorptive cell monolayers for simulating drug absorption is through the use of biphasic media. [91] [92] [93] In this case, the drug is dissolved in the aqueous phase and partitions in the organic phase. The drug concentration profile that is acquired from the organic phase could be an effective surrogate of the amount of drug available for absorption. Vagani et al., [94] developed a system by combining biphasic media and a flow through (USP IV) technique. In particular, the USP apparatus IV is combined with a USP II apparatus. The cells from the USP IV apparatus are used to hold the formulations and the dissolution vessels from the USP II apparatus contain the biphasic dissolution media, maintained at 37°C. This system has also been used by Shi et al. [95] Overall, this system established good IVIVC with the drug concentrations obtained in the organic phase and the biopharmaceutical performance of the different formulations was well discriminated. Tsume et al., [96] combined the gastrointestinal simulator (GIS) introduced by Takeuchi et al., with biphasic media to investigate whether the addition of the organic layer would lead to better predictions of the plasma concentrations of two poorly soluble, weakly basic compounds, raloxifene and ketoconazole. Indeed, the results of ketoconazole showed slower decline of drug concentration in the small intestinal compartments with the presence of the organic phase, than those without the addition of the biphasic system, thus providing another calculated precipitation rate constant. Incorporation of these data to physiologically based pharmacokinetic (PBPK) models and simulation with Gastroplus â suggested a slight improvement in the in vivo predictions of ketoconazole. The combination of GIS with an organic layer provided also information about the partitioning characteristics of these two drugs to the organic phase.
To account for the absorption process, Hate et al., [97] developed an apparatus coupled with a high surface membrane area. The apparatus consisted of a donor compartment, where drug dissolution takes place, a buffer reservoir and a receiver chamber, to collect drug after diffusion through the membrane (Figure 10) . A hollow fibre membrane was used to simulate intestinal absorption, due to its high surface area per unit volume of fluid, thus facilitating higher mass transfer. A pump is used to control the transfer of fluid. In particular, fluid from the donor compartment is transferred to the inner side of the hollow membrane, where at the same time fluid from the reservoir compartment is transferred to the outer side of the hollow membrane. The drug diffused through the membrane into the fresh buffer, which was collected into the receiver chamber. The donor fluid emerging from the membrane module was then recycled back into the donor chamber. Three different formulations of the weakly basic drug nevirapine were tested using this apparatus. Initially, the media in the donor chamber was 0.1 M HCL. After 30 min, the pH was adjusted to pH 6.5 using 0.17 M Na 2 HPO 4 and the absorption system was connected. When assessing the performance of nevirapine tablets and powder, rapid precipitation of nevirapine down to its equilibrium solubility was observed in the donor compartment, upon transition to pH 6.5. When a precipitation inhibitor (HPMC-AS) was used, there was no precipitation observed in the donor chamber for up to 160 min, while an increase in drug concentration was observed in the receiver chamber. However, Figure 10 Schematic of the apparatus used by Hate et al. [97] The hollow fibre membrane is represented by the grey and black tube. no significant differences were observed in the dissolution profiles, when the performance of nevirapine tablet, with or without the addition of the absorption membrane was assessed. Overall, the apparatus could be a useful tool for formulation screening and for assessing drug precipitation or supersaturation. However, more data is needed to support its further application. The artificial membrane insert system (AMI system) was proposed by Berben et al., [98] as a method to simulate the passive absorption of drug in the intestine without the use of cells based systems, such as Caco-2. The AMI system consists of a regenerated cellulose membrane mounted between two plastic rings, as shown in Figure 11 , [98] and has shown comparable results to Caco-2 cells when assessing the permeability coefficients of poorly soluble drugs. To study the interplay between supersaturation, precipitation and absorption, Berben et al., [99] carried out an experiment to examine the potential of the AMI system using loviride, posaconazole, itraconazole and fenofibrate. Initially, samples were added to Level II fasted state simulated gastric fluid (FaSSGF) with constant stirring at 300 rpm, with magnetic stirrers. After 15 min, the acidic medium was added to concentrated Level II FaSSIF. Following another 15-min period of stirring, a sample of the intestinal fluid (665 ll) was added to the donor side of the AMI system. In the case of loviride, the meta-stabilised supersaturated state resulted in higher concentrations of drug in the acceptor compartment, whereas lower concentrations of drug were found in the acceptor chamber when precipitation was induced. An enhanced permeation into the acceptor compartment was also observed for posaconazole when it was administered as an acidified suspension compared with a neutral suspension using the AMI system (concentration at 120 min: acidified suspension: 1.12 AE 0.01 nmol and neutral suspension: 0.44 AE 0.01 nmol). This trend corresponded to an in vivo study carried out by Hens et al., [12] which found a twofold increase in AUC 0-8h following administration of the acidified suspension vs the neutral suspension. When evaluating the performance of the AMI system using three different bio-enabling formulations: Sporanox â solution (itraconazole), Lipanthyl â capsules and Lipanthylnano â tablets (fenofibrate), the drug concentrations achieved in the acceptor compartment of the AMI system were qualitatively well correlated with the respective intraluminal drug concentrations. However, further validation of the setup is required with other compounds. Overall, the AMI system when coupled with the two-stage dissolution test proved to be a useful early screening tool in assessing the possible in vivo precipitation of APIs as well as the performance of formulated drug products. Finally, the TNO TIM-1 is a computer controlled multi-compartmental model of the human GIT. It was developed by the TNO Nutrition and Food Research centre based on data from in vivo human studies [100] and simulates the dynamic digestive and physiological processes in the stomach and small intestine. [101] The TIM-1 system models the absorption of small molecules through their uptake from filtration membrane systems or dialysis in the ileal and jejunal sections of the system. In this way, the amount of drug in solution which is available for absorption (expressed as 'bioaccessibility') can be measured. However, some active processes such as active absorption, efflux and intestinal metabolism are not modelled by this system. It has been suggested that the TNO TIM-1 system can be coupled with other intestinal absorption systems to facilitate modelling of these processes, thus enabling an estimation of oral bioavailability of compounds. [102] The majority of studies carried out with the TIM-1 have focused on the absorption of nutritional compounds and there are only a limited number of published studies focusing on the uptake of pharmaceutical compounds. [103] [104] [105] [106] The biorelevance of the TIM-1 system would indicate significant potential to model precipitation of drug in the GIT. However, the time required for set up and the Figure 11 Schematic of the AMI-system proposed by Berben et al. [99] Reproduced with permission from Elsevier.
limited throughput are significant limitations when considering its potential use as a tool to predict in vivo precipitation. Recently, Van Den Abeele et al., [107] have used an updated version of TIM-1 (TIMagc) with the aim of investigating the intraluminal behaviour of diclofenac in the fasted and fed state. The results obtained from the in vitro setup were compared with intraluminal and systemic data collected from healthy volunteers after the administration of diclofenac tablets along with 240 ml of water. The data obtained with this method can suggest slow dissolution or precipitation of diclofenac in the stomach, but it was not possible to mechanistically discern between these two mechanisms. The potential of TIM-1 to assess precipitation in the upper small intestine must be further investigated using weakly basic drugs and bio-enabling formulations.
Coupling full scale in vitro testing with physiologically based pharmacokinetic modelling
Physiologically based pharmacokinetic modelling has been widely used and rapidly developed in the last years with many applications in academia and in the pharmaceutical industry. Furthermore PBPK modelling has gained acceptance at various regulatory agencies as part of the submission package. In 2016 the Committee for Medicinal Products for Human Use (CHMP) of EMA and FDA published a draft guidance regarding the qualification of PBPK modelling, concerning its use to support marketing authorisation. [108, 109] This guidance aims to provide general information on which details should be included in a PBPK modelling report and which elements are needed in order for a PBPK platform to be qualified and evaluated for an intended purpose. Generally, PBPK modelling can be used for the prediction of human PK profiles from preclinical data and it is a useful tool for evaluating and optimising a clinical trial design. It can also be utilised for extrapolating the drug's pharmacokinetic behaviour in healthy volunteers to patient populations, where clinical studies are difficult to be conducted. In order for a successful drug model to be built using the 'bottom-up' approach, the quality of the input data is of high importance. [110] Coupling in vitro data with in silico methods can be very important in optimising and validating both in vitro and in silico models. Commercially available software, such as Simcyp â Simulator and , or open source and in-house modelling platforms can incorporate in vitro data of supersaturation and precipitation kinetics. This can then lead to a better understanding of the importance of supersaturation or precipitation in vivo. In many cases, combination of the in silico and in vitro methods to assess supersaturation and precipitation has proven to be successful. [61, [111] [112] [113] Gastroplus â software handles precipitation by incorporating a mean precipitation time. This parameter is the mean time for particles to precipitate from solution, when the local concentration exceeds the drug solubility and it is a function of luminal pH. Default precipitation time is 900 s, which was determined from exponential fit to the dipyridamole transfer data, published by Kostewicz et al. [62] Certara â recently introduced the 'Simcyp In Vitro Data Analysis Toolkit-SIVA' which is designed to model in vitro experiments and estimate parameters for input to in vivo simulations with the mechanistic PBPK Simcyp â Simulator. For modelling supersaturation and precipitation, SIVA and Simcyp â Simulator use an empirical approach based on critical supersaturation concentration and precipitation rate constant obtained in in vitro experiments. [111] One issue with the available software is that they rely mostly on precipitation kinetics which at best have been estimated with non-validated in vitro setups. Validation of in vitro methodologies should ideally be based on intraluminal data in humans. It should also be noted that it is difficult to build a successful, validated model which can predict the behaviour of a drug in vivo, especially for BCS II, III and IV drugs. [114] Nonetheless, coupling in vitro data with in silico models can help also to optimise the in vitro techniques which are currently being used and understand which are the critical parameters for drug supersaturation and precipitation.
Conclusions
The increasing prevalence of poorly soluble drugs and use of bio-enabling formulations to achieve supersaturated states in vivo has triggered great interest in in vitro precipitation modelling. Overall, much progress has been made from the standard equipment used in QC testing and various in vitro models have been developed. Small-scale tests are beneficial, especially in early stage of drug development, as drug quantities are often limited. Employing a small-scale approach also facilitates the rapid parallel screening of multiple prospective formulations. Multicompartment models have proven useful to evaluate precipitation of drug upon transfer from the gastric to the intestinal environment. However, it would be reasonable to state that no single in vitro test is suitable for modelling precipitation in all circumstances. Further progress is still to be made to improve the predictive capabilities of such models, especially in terms of simulating the absorption of drug along the intestinal lumen. Coupling the results of in vitro tests with PBPK modelling has significant potential and must be investigated further. Improving the biopharmaceutics tools to predict in vivo precipitation will be a key step to improving the efficacy and reducing the development costs of medicines.
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